Drug intelligence / Profile preview

PD-Co-005

Development stage: Preclinical
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Peptides

Overview

PD-Co-005 is a preclinical-stage peptide therapeutic candidate being developed by Chengdu Peide Biopharmaceutical for the treatment of hereditary angioedema (HAE). The drug is designed to act as an inhibitor of plasma kallikrein (PKal), a key enzyme in the contact activation pathway. By inhibiting PKal, PD-Co-005 aims to prevent the excessive production of bradykinin, which is responsible for the localized swelling and pain associated with HAE attacks. The program is currently in the lead optimization or preclinical candidate (PCC) stage.

Targets

KLKB1 (Plasma kallikrein)

Beyond the preview

Go deeper on PD-Co-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-Co-005.

Explore the full profile